Addex Therapeutics
ADXN
2 hedge funds and large institutions have $227K invested in Addex Therapeutics in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
49% more capital invested
Capital invested by funds: $152K → $227K (+$75K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$13.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$242 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
1
Caxton Corporation
Princeton,
New Jersey
| $213K | -$242 | -1 | -0.1% |
|
|
2
UBS Group
Zurich,
Switzerland
| $14K | +$13.8K | +57 | New |
|
ADXN Hedge Fund Activity: Q3 2020 in Review
2 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q3 2020, worth a combined $227K — up 49% from $152K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ADXN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $13.8K. The largest seller was Caxton Corporation, cutting an estimated $242.
- 2 institutional investors held Addex Therapeutics (ADXN) as of Q3 2020, up from 1 in Q2 2020.
- Funds reported $227K of Addex Therapeutics stock for Q3 2020, up 49% quarter-over-quarter.
- 1 fund opened new Addex Therapeutics positions in Q3 2020 and 0 closed out, a net change of +1 holder.
- The largest Addex Therapeutics buyer in Q3 2020 was UBS Group, an estimated $13.8K added.
- The largest Addex Therapeutics seller in Q3 2020 was Caxton Corporation, an estimated $242 sold.
Based on aggregated 13F filings for Q3 2020.